{"paper_id":"93763787-250d-4fb9-bae7-1a5ed9205bdf","body_text":"Abstract\nPurpose\nTo evaluate the effects of a continuous regimen combined oral contraceptive (COC) containing 2 mg dienogest and 30 µg ethinyl estradiol (DNG/EE) compared to a 21/7 regimen on the quality of life (QoL) and sexual function in women affected by endometriosis-associated pelvic pain.\nMethods\nSixty-three women constituted the Study group treated with DNG/EE COC continuous regimen; 33 women were given DNG/EE COC in a 21/7 regimen. To define the endometriosis-associated pelvic pain, the Visual Analogic Scale was used. The Short Form-36, Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess QoL, sexual function and sexual distress, respectively. The study included two follow-ups.\nResults\nAt 3 and 6 months of treatment there was an improvement in pain of the Study group (p < 0.001). The Control group underwent pain improvement at the second follow-up (p < 0.05). At the first and the second follow-ups, the Study group reported QoL improvements in all categories (p < 0.001). The Control group reported QoL improvements in all categories at the second follow-up (p < 0.05). At the first and the second follow-ups of the Study group, the FSFI total score had risen (p < 0.001), and the FSDS score had dropped (p < 0.001). An improvement of the FSFI score and a reduction of the FSDS score of the Control group was observed at the second follow-up (p < 0.001), but not at the first follow-up (p = NS).\nConclusions\nWomen on DNG/EE COC continuous regimen reported a reduction of endometriosis-associated pelvic pain and there was an improvement of their sexual activity and their QoL that was better than the DNG/EE 21/7 conventional regimen.\nSimilar content being viewed by others\nReferences\nHuntington A, Gilmour JA (2005) A life shaped by pain: women and endometriosis. J Clin Nurs 14:1124–1132\nDenny E (2004) Women’s experience of endometriosis. J Adv Nurs 46:641–648\nNnoaham KE, Sivananthan S, Hummelshoj L, Jenkinson C, Webster P, Kennedy SH, Zondervan KT (2009) Multi-centre studies of the global impact of endometriosis and the predictive value of associated symptoms. J Endometr 1:36–45\nSepulcri RP, do Amarai VF (2009) Depressive symptoms, anxiety, and quality of life in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 142:53–56\nHummelshoj L, De Graaff A, Dunselman G, Vercellini P (2014) Let’s talk about sex and endometriosis. J Fam Plann Reprod Health Care 40:8–10\nHyun Shin JA, Howard FM (2011) Management of chronic pelvic pain. Curr Pain Headache Rep 15:377–385\nSinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, Stratton P (2008) Differences in characteristics of 1.000 women with endometriosis based on extent of disease. Fertil Steril 89:538–545\nRogers PA, D’Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, Montgomery GW, Rombauts L, Salamonsen LA, Zondervan KT (2009) Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci 16:335–346\nKennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E, ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20:2698–2704\nDunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W, European Society of Human Reproduction and Embryology (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29:400–412\nVercellini P, Viganò P, Somigliana E, Fedele L (2014) Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 10:261–275\nJeng CJ, Chuang L, Shen J (2014) A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother 15:767–773\nLeone Roberti Maggiore U, Remorgida V, Scala C, Tafi E, Venturini PL, Ferrero S (2014) Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand 93:239–247\nEdelman A, Micks E, Gallo MF, Jensen JT, Grimes DA (2014) Continuous or extended cycle versus cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 7:CD004695\nVercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG (2005) Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate. Fertil Steril 84:1375–1387\nVercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R (2003) Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80:560–563\nCheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakult T (2012) Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain; a randomized comparative trial. Gynecol Obstet Invest 74:151–156\nDmitrovic R, Kunselman A, Legro R (2012) Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 119:1143–1150\nCoffee AL, Sulak PJ, Kuehl TJ (2007) Extended-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75:444–449\nBirtch RL, Olatunbosun OA, Pierson RA (2006) Ovarian follicular dynamics during conventional versus continuous oral contraceptive use. Contraception 73:235–243\nAllen C, Hopewell S, Prentice A, Gregory D (2009) Nonsteroidal antiinflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2:CD004753\nThe Practice Committee of the American Society for Reproductive Medicine (2014) Treatment of pelvic pain associated with endometriosis. Fertil Steril 101:927–935\nBizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, Salvatore S, Candiani M, Venturini PL, Ferrero S (2014) Dienogest in the treatment of endometriosis. Expert Opin Pharmacother 15:1889–1902\nSchindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008) Classification and pharmacology of progestins. Maturitas 61:171–180\nKlipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B (2012) Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 52:1704–1713\nSitruk-Ware R, Nath A (2010) The use of newer progestins for contraception. Contraception 82:410–417\nGrandi G, Xholli A, Napolitano A, Palma F, Cagnacci A (2015) Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci 22:626–632\nGallagher EJ, Liebman M, Bijur PE (2001) Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 38:633–638\nWare JE, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M (1998) The factor structure of the SF-36 Health Survey in 10 countries: results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 51:1159–1165\nBasson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW (2004) Revised definitions of women’s sexual dysfunction. J Sex Med 1:40–48\nNappi RE, Albani F, Vaccaro P, Gardella B, Salonia A, Chiovato L, Spinillo A, Polatti F (2008) Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol 24:214–219\nDerogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J (2002) The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal in distress women. J Sex Marital Ther 28:317–330\nBourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M (2015) Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update 21:136–152\nBorghese B, Sibiude J, Santulli P, Lafay Pillet MC, Marcellin L, Brosens I, Chapron C (2015) Low birth weight is strongly associated with the risk of deep infiltrating endometriosis: results of a 743 case–control study. PLoS One 10:e0117387\nDi Donato N, Montanari G, Benfenati A, Leonardi D, Bertoldo V, Monti G, Raimondo D, Seracchioli R (2014) Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol 181:289–293\nVercellini P, Consonni D, Barbara G, Buggio L, Frattaruolo MP, Somigliana E (2014) Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online 28:704–713\nKoga K, Takamura M, Fujii T, Osuga Y (2015) Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril 104:793–801\nMiyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y (2014) Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 30:644–648\nFerrari S, Persico P, Di Puppo F, Vigano P, Tandoi I, Garavaglia E, Giardina P, Mezzi G, Candiani M (2012) Continuous low-dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal endoscopic ultrasonography. Acta Obstet Gynecol Scand 91:699–703\nCaruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A (2015) Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest 38:1211–1218\nNakamura M, Katsuki Y, Shibutani Y, Oikawa T (1999) Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 386:33–40\nWiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Lange E, Mellinger U, Palombo-Kinne E, Kuhl H (2011) Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 84:133–143\nHee L, Kettner LO, Vejtorp M (2013) Continuous use of oral contraceptives: an overview of effects and side-effects. Acta Obstet Gynecol Scand 92:125–136\nReid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD (2010) Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception 82:497–502\nNappi RE, Kaunitz AM, Bitzer J (2015) Extended regimen combined oral contraception: a review of evolving concepts and acceptance by women and clinicians. Eur J Contracept Reprod Health Care 17:1–9\nPanicker S, Mann S, Shawe J, Stephenson J (2014) Evolution of extended use of the combined oral contraceptive pill. J Fam Plann Reprod Health Care 40:133–141\nStein SL (2013) Chronic pelvic pain. Gastroenterol Clin N Am 42:785–800\nGreene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N (2009) Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril 91:323–329\nLaufer MR (2008) Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest 66(Suppl 1):19–27\nVercellini P, Frattaruolo MP, Somigliana E, Jones GL, Consonni D, Alberico D, Fedele L (2013) Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod 28:1221–1230\nMcCormack PL (2010) Dienogest: a review of its use in the treatment of endometriosis. Drugs 70:2073–2088\nCaruso S, Malandrino C, Cicero C, Ciancio F, Cariola M, Cianci A (2013) Quality of sexual life of women on oral contraceptive continued-regimen: pilot study. J Sex Med 10:460–466\nEdelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA (2005) Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 3:CD004695\nSauer U, Mann S, Brima N, Stephenson J (2013) Offering extended use of the combined contraceptive pill: a survey of specialist family planning services. Int J Womens Health 5:613–617\nAcknowledgments\nThe authors wish to thank: The Scientific Bureau of the University of Catania, Italy, for language support.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflict of interest\nThe authors declare that they have no conflict of interest.\nEthical approval\nAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.\nInformed consent\nInformed consent was obtained from all women included in the study.\nRights and permissions\nAbout this article\nCite this article\nCaruso, S., Iraci, M., Cianci, S. et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 39, 923–931 (2016). https://doi.org/10.1007/s40618-016-0460-6\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s40618-016-0460-6","source_license":"CC0","license_restricted":false}